US equities |
MU $938.43 ▼-5.12% META $766.35 ▲+3.15% NVDA $224.80 ▼-0.67% SNDK $1,438.86 ▼-3.26% AAPL $346.34 ▲+1.57% MSFT $547.29 ▲+1.13% SPCX $156.68 ▼-4.12% AMD $587.12 ▼-1.20%
FinancialContent

TG Therapeutics, Inc. - Common Stock (NQ:TGTX)

54.03 -1.24 (-2.24%)
Delayed Quote Updated: 11:18 AM EDT, Oct 13, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about TG Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
13 14 Next >
TG Therapeutics (NASDAQ:TGTX) Pairs Strong Growth With a High-Quality Breakout Setup ↗
Via Chartmill
News headline image
TG Therapeutics Announces Publication of Five-Year Comparative Analysis of BRIUMVI Versus Ocrelizumab and Ofatumumab in Relapsing Multiple Sclerosis
From TG Therapeutics, Inc.
Via Business Wire
News headline image
TG Therapeutics Announces Schedule of Data Presentations at MSToronto2026
From TG Therapeutics, Inc.
Via Business Wire
TG Therapeutics (NASDAQ:TGTX) Emerges as an Affordable Growth Play in Biotech ↗
Via Chartmill
TG Therapeutics (NASDAQ:TGTX) Combines Strong Growth With a Tight Technical Breakout Setup ↗
Via Chartmill
TG Therapeutics (NASDAQ:TGTX): A Fitting Candidate for Affordable Growth ↗
Via Chartmill
TG Therapeutics (NASDAQ:TGTX) Combines Strong Growth with a Breakout Setup ↗
Via Chartmill
TG Therapeutics (NASDAQ:TGTX) Falls as Q2 Revenue Beats but EPS Misses, Guidance Raised Below Estimates ↗
Via Chartmill
TG Therapeutics (NASDAQ:TGTX) Meets Minervini's Trend Template with Accelerating Growth ↗
Via Chartmill
News headline image
TG Therapeutics Eyes $1B Run Rate as BRIUMVI Gains MS Market Share ↗
TG Therapeutics (NASDAQ:TGTX) Chairman, President and Chief Executive Officer Mike Weiss said the company’s multiple sclerosis therapy, BRIUMVI, has captured more than one-third of the intravenous... 
Via MarketBeat
MissionIRNewsBreaks – Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) Advances Lucid-MS Toward Phase 2 Trial Following FDA Clearance
Via Investor Brand Network
Historic First in MS Treatment Could Reshape a Multibillion-Dollar Therapeutics Market
Via Investor Brand Network
MissionIRNewsBreaks – Quantum BioPharma Ltd. (NASDAQ: QNTM) Advances Lucid-MS Toward Phase 2 Trial Following FDA Clearance
Via Investor Brand Network
TG THERAPEUTICS INC (NASDAQ:TGTX): High-Growth Momentum Meets Minervini Trend Template Technical Strength ↗
Via Chartmill
TG THERAPEUTICS INC (NASDAQ:TGTX) Screens as Affordable Growth Play with Strong Revenue Surge and Discounted Valuation ↗
Via Chartmill
TG Therapeutics (NASDAQ:TGTX) Q1 2026 Earnings Beat Revenue Guidance but Miss EPS Estimates ↗
Via Chartmill
Topics Earnings
News headline image
Historic First in MS Treatment Could Reshape a Multibillion-Dollar Therapeutics Market
From BioMedWire
Via GlobeNewswire
News headline image
TG Therapeutics Conference: 908 Devices Bets on Handheld Drug, Chemical Detection ↗
908 Devices outlined its strategy to focus exclusively on handheld chemical and drug detection technologies for public safety and defense markets, following the divestiture of its life-sciences... 
Via MarketBeat
News headline image
TG Therapeutics (TGTX) Q2 2026 Earnings Call Transcript ↗
BRIUMVI revenue surged 64% year-over-year as patient starts hit record levels. 
Via The Motley Fool
Topics Earnings
News headline image
TG Therapeutics Q2 Earnings Call Highlights ↗
TG Therapeutics (NASDAQ:TGTX) reported second-quarter 2026 revenue of $240 million and raised its full-year sales outlook for BRIUMVI, its treatment for relapsing multiple sclerosis, as the company... 
Via MarketBeat
Topics Earnings
News headline image
2 Fast-Growing Pharmaceutical Stocks to Buy Now ↗
Incyte and TG Therapeutics are seeing strong share growth, backed up by booming revenue and earnings. 
Via The Motley Fool
The Quest to Repair What Multiple Sclerosis Takes Away
Via Investor Brand Network
InvestorNewsBreaks – Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) Advances Lucid-MS Toward Phase 2 Trials for Multiple Sclerosis
Via Investor Brand Network
News headline image
The Quest to Repair What Multiple Sclerosis Takes Away
From BioMedWire
Via GlobeNewswire
News headline image
TG Therapeutics Stock Surges After Drug Trial Update ↗
Shares of TG Therapeutics Inc (NASDAQ: TGTX) are climbing Wednesday after early-stage clinical trial data for new BRIUMVI MS formulation. 
Via Benzinga
News headline image
Vericel Revenue Jumped 20%. One Biotech Investor Just Reported Adding $63 Million More ↗
Vericel develops cell therapies for cartilage repair and burn care, serving hospitals and clinics across the United States. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Structure Therapeutics Stock Is Up 47%, but One Fund Just Fully Exited a $2.6 Million Position ↗
This clinical-stage biotech develops oral therapeutics for chronic diseases, targeting large global markets with unmet medical needs. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Why One Fund’s $4 Million Alumis Buy Looks Like a Bet on a Breakthrough Autoimmune Drug ↗
Alumis develops clinical-stage therapies targeting autoimmune and neuroinflammatory diseases with a focus on TYK2 inhibition technology. 
Via The Motley Fool
News headline image
TG Therapeutics (TGTX) Q1 2026 Earnings Transcript ↗
TG Therapeutics (TGTX) Q1 2026 Earnings Transcript 
Via The Motley Fool
News headline image
TGTX Q1 2025 Earnings Call Transcript ↗
TGTX Q1 2025 Earnings Call Transcript 
Via The Motley Fool
Topics Earnings
< Previous 1 2 3 4 5 6 7 8 9
...
13 14 Next >